Legend Biotech's Earlier-Line Mirage: the mix moved, the revenue didn't
CARVYKTI's 2L/3L share hit 50% of U.S. apheresis volume while U.S. sales went flat — and on her first call, the new CEO quietly walked the top end of consensus back
LEGN · Earnings Call · 2026-11-10
The first call of the Zhang era
Ingrid Zhang opened her debut earnings call with a three-part catechism: “My priorities as CEO are clear: number one, maximize CARVYKTI; number two, advance our next-generation pipeline; and number three, strengthen execution on all fronts to deliver sustained profitability.” — Ingrid Zhang, Chief Executive Officer · 2026-11-10 The quarter she inherited looks like a beat on nearly every line. CARVYKTI net trade sales rose roughly 36% year over year to about $710 million. Gross margin came in at 58% against guidance in the lower 50s. Adjusted net income was $55.6 million, or $0.14 per diluted share, versus an $18.7 million adjusted loss a year earlier. The balance sheet holds roughly $853 million in cash and time deposits with no long-term debt. But the composition is where the story lives. U.S. net trade sales grew 19%; ex-U.S. grew 86%. And U.S. sales were roughly flat sequentially — the precise fault line every analyst on the call probed.Mix shift without revenue shift
Alan Bash delivered the number the company has been building toward for a year: “patients in the second and third lines represented 50% of CARVYKTI apheresis volume in the U.S. in the third quarter of 2026, which is a significant increase from the 41% in the first quarter of 2026 and 29% in the first quarter of 2025.” — Alan Bash, Chief Commercial Officer or Head of Commercial · 2026-11-10 That is genuine share gain in the earliest approved lines — the segment management has called the fastest-growing part of the franchise since the spring. Jon Miller of Evercore asked the obvious question: “It seems like you're really accelerating that with the NCCN guideline, but it doesn't seem to be translating directly to sales growth in the U.S.” — Jonathan Miller, Analyst · 2026-11-10 The answer was a longer selling cycle, more physician education, and TECVAYLI's earlier-line approval this year. In other words, the mix is migrating faster than the base is growing — earlier-line patients are replacing later-line volume rather than adding to it. That distinction matters because the company's sequential-growth promise has quietly changed shape. In March, Ying Huang was categorical: “we are planning and also we're committed to sequential growth throughout the year that includes all 4 quarters of 2026.” — Ying Huang, Chief Executive Officer · 2026-03-10 In August, Carlos Santos repeated the frame for the back half: “we are indicating a global growth on a sequential basis across the balance of the 2 quarters in the second half of 2026.” — Alan Bash, Interim Chief Executive Officer · 2026-08-11 This week, the language became bracketing rather than commitment — Q4 consensus sits at the high end of internal scenarios, and 2027 likewise, driven by what Santos called “launch delays in the OUS markets, and we're seeing a slower earlier line share growth in the U.S. than we had initially anticipated.” — Carlos Santos, Chief Financial Officer · 2026-11-10That is not a guide-down in so many words. It is the softest possible way to say the sell side is too high — twice over, for two different years. The growth is now coming disproportionately from ex U.S. markets: 20 countries live, with Italy newly contributing alongside Germany and Spain, and the single-payer argument for a one-time infusion doing real work.We do expect to see double-digit growth year-over-year for CARVYKTI in '27. However, the current net trade sales consensus for 2027 would be at the higher end of the scenarios that we're currently anticipating.
NCCN: a new lever, and a genuinely new keyword
For the first time in Legend's keyword history, NCCN guideline sits near the very top of the company's thematic stack — it appears in no prior quarter's trajectory. The September update told community oncologists three things: refer myeloma patients to a T-cell-capable center at first relapse, treat CAR-T as preferred over T-cell engagers when both are viable, and minimize prior BCMA exposure before BCMA CAR-T. The companion phrase CAR T before bispecifics is new to this call as well. Strategically this is the right lever, and it is not small: management estimates 80%–85% of second- and third-line patients remain BCMA-naive. But guidelines do not write prescriptions; education does, and Bash conceded the education cycle is long. The recurring theme of CAR T at first relapse, now several quarters old, is being re-underwritten by a document rather than by new data.ASH and the in vivo option
Where the call genuinely opened new ground was BCMA CAR T's next-generation sibling. LB2501, the in vivo CD19/CD20 program, cleared its IND during the quarter, and the ASH abstract expanded to 19 patients across three dose levels. At dose level 2, eight patients produced 100% overall and complete response rates; at dose level 3, five patients delivered roughly 60%. Yuhong Qiu noted “no DLT, no ICANS, no non-ICAN neurotoxicities were reported.” — Yuhong Qiu, Senior Scientist or Research Leader · 2026-11-10 The shape is a threshold, not a dose-response curve — nothing at DL1, everything at DL2 — which is either the most interesting thing in the abstract or the thing that makes the next cohort the whole story. The global tape has already begun paying for this kind of exposure: B cell malignancy is among the strongest 90-day advancers across biotech in the Know Trend theme tape, up roughly 45% on names like ABBV, GMAB and ONC. Legend's ASH readout lands into a market that has decided B-cell biology is investable again. What did not get said is nearly as telling. LB2505, the BCMA-directed in vivo asset, drew no update at all — and when Yaron Werber asked directly whether Johnson & Johnson has formally opted in, the answer was a flat refusal to elaborate, twice. In August the company was happy to disclose a China investigator-initiated study for that program. The silence is a change in posture, not an absence of news.The quality of the profit
The margin story is real — manufacturing efficiency pushed gross margin to 58%, and Q4 is guided to the high 50s. The operating leverage is real too, but less clean than the headline. The quarter included a $24 million one-time time credit tied to share-based compensation; stripping it out, SG&A rose 8% and total operating expenses fell 6%. “Excluding the impact of the one-time credit related to share-based compensation, operating margin improved to a positive 6% compared to a negative 16% in the third quarter of 2025.” — Carlos Santos, Chief Financial Officer · 2026-11-10 Still a swing of 22 points — but a chunk of the R&D decline came from late-stage BCMA frontline studies rolling off, a tailwind that does not recur.The bottom line
Legend still has the best-in-class argument. Bash's competitive dismissal was the sharpest line of the morning:Five-year CARTITUDE-2 Cohort A data — half of patients alive and progression-free at five years versus 33% in CARTITUDE-1 — is a genuinely differentiated asset. The $5 billion-plus peak and the CARTITUDE-5 frontline readout, now "soonest 2027," remain the real prize. But the bridge to that prize is the U.S. earlier-line pull-through, and on this call the company told you that bridge is being built more slowly than it promised six months ago. The mix is working. The P&L is working. The revenue line has not yet caught up — and the new CEO's first act was to make sure nobody was modeling the top end of the range.We treat more patients in a week than they've shown in their entire program.